Atenolol
- Atenolol
- No Brand Name
- Tablet
- 50mg
- Blister
- 100 Tablets
-
• Hypertension
• Angina Pectoris
• Angina Pectoris
Mechanism of Action
Blocks response to beta-adrenergic stimulation, cardioselective for beta1 receptors at low doses, with little or no effect on beta2 receptors
Pharmacokinetics
Bioavailability: 46-60%
Excretion: Feces (50%), urine (40-50%)
Contraindications
• 2°/3° heart block in patients without pacemaker
• Cardiogenic shock
• Sinus bradycardia
• Sinus node dysfunction
• Hypersensitivity
• Uncompensated cardiac failure
• Pulmonary edema
Adverse Reactions
Fatigue, Hypotension, Bradycardia, Cold extremities, Postural hypotension, Depression, Nausea, Dreaming, Drowsiness, Diarrhea, Fatigue, Leg pain, Lethargy, Lightheadedness, Vertigo, Dyspnea, 2°/3° atrioventricular (AV) block
Major Drug Interactions
-
Warnings
• Ischemic heart disease may be exacerbated after abrupt withdrawal
• Hypersensitivity to catecholamines has been observed during withdrawal
• Exacerbation of angina and, in some cases, MI may occur after abrupt discontinuance
• When long-term beta blocker therapy (particularly with ischemic heart disease) is discontinued, dosage should be gradually reduced over 1-2 weeks with careful monitoring
• If angina worsens markedly or acute coronary insufficiency develops, beta-blocker administration should be promptly reinitiated, at least temporarily (in addition to other measures appropriate for unstable angina)
• Patients should be warned against interruption or discontinuance of beta-blocker therapy without physician advice
• Because coronary artery disease (CAD) is common and may be unrecognized, beta-blocker therapy must be discontinued slowly, even in patients treated only for hypertension
Recommendations for Patient
-
Pregnancy Considerations
Category: D
Breastfeeding Considerations
Drug enters breast milk, neonates born to mothers who are receiving atenolol at parturition or breastfeeding may be at risk for hypoglycemia and bradycardia, use with caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: Maybe acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Blocks response to beta-adrenergic stimulation, cardioselective for beta1 receptors at low doses, with little or no effect on beta2 receptors
Pharmacokinetics
Bioavailability: 46-60%
Excretion: Feces (50%), urine (40-50%)
Contraindications
• 2°/3° heart block in patients without pacemaker
• Cardiogenic shock
• Sinus bradycardia
• Sinus node dysfunction
• Hypersensitivity
• Uncompensated cardiac failure
• Pulmonary edema
Adverse Reactions
Fatigue, Hypotension, Bradycardia, Cold extremities, Postural hypotension, Depression, Nausea, Dreaming, Drowsiness, Diarrhea, Fatigue, Leg pain, Lethargy, Lightheadedness, Vertigo, Dyspnea, 2°/3° atrioventricular (AV) block
Major Drug Interactions
-
Warnings
• Ischemic heart disease may be exacerbated after abrupt withdrawal
• Hypersensitivity to catecholamines has been observed during withdrawal
• Exacerbation of angina and, in some cases, MI may occur after abrupt discontinuance
• When long-term beta blocker therapy (particularly with ischemic heart disease) is discontinued, dosage should be gradually reduced over 1-2 weeks with careful monitoring
• If angina worsens markedly or acute coronary insufficiency develops, beta-blocker administration should be promptly reinitiated, at least temporarily (in addition to other measures appropriate for unstable angina)
• Patients should be warned against interruption or discontinuance of beta-blocker therapy without physician advice
• Because coronary artery disease (CAD) is common and may be unrecognized, beta-blocker therapy must be discontinued slowly, even in patients treated only for hypertension
Recommendations for Patient
-
Pregnancy Considerations
Category: D
Breastfeeding Considerations
Drug enters breast milk, neonates born to mothers who are receiving atenolol at parturition or breastfeeding may be at risk for hypoglycemia and bradycardia, use with caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: Maybe acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Send to other people